In another patient case, panelists break down third-line therapy options for someone with HER2+ metastatic breast cancer and lung disease.
Drs. Gupta and Brown review a recently published paper by Grivas et al. (2019) on the use of checkpoint inhibitors for maintenance therapy to prolong the benefits of frontline therapy while minimizing toxicity in solid tumors.
Moving to optimal treatment approaches in second-line therapy, experts close out a patient case of HER2+ metastatic breast cancer.
Patients who were given extended 5-year treatment with letrozole plus 2 to 3 years of tamoxifen experienced an improvement in disease-free survival compared with 2 to 3 years of treatment with letrozole.
Imaging drug imaging drug pafolacianine was approved by the FDA to detect ovarian cancer lesions in patients during surgery.
Men with localized prostate cancer were most likely to select treatment with radiotherapy over surgery and its associated adverse effects.
Late-stage cancer and poor outcomes for patients may occur as a result of low screening numbers during the COVID-19 pandemic.
Breast cancer survivors who are minorities or medically underserved appear to experience a benefit in health-related quality of life after taking part in a community-based physical activity program.
As the year 2021 comes to a close, CancerNetwork® reviews ongoing clinical research and upcoming innovations in the non–small cell lung cancer space.
Don Dizon, MD, FACP, FASCO, discusses the need to improve treatment strategies for transgender patients with cancer.